- Home
- CTRM vs LGVN Comparison
CTRM vs LGVN Comparison
Compare CTRM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- LGVN
- Stock Information
- Founded
- CTRM 2016
- LGVN 2014
- Country
- CTRM Cyprus
- LGVN United States
- Employees
- CTRM N/A
- LGVN N/A
- Industry
- CTRM Marine Transportation
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CTRM Consumer Discretionary
- LGVN Health Care
- Exchange
- CTRM Nasdaq
- LGVN Nasdaq
- Market Cap
- CTRM 25.0M
- LGVN 25.2M
- IPO Year
- CTRM N/A
- LGVN 2021
- Fundamental
- Price
- CTRM $2.38
- LGVN $1.70
- Analyst Decision
- CTRM
- LGVN Strong Buy
- Analyst Count
- CTRM 0
- LGVN 3
- Target Price
- CTRM N/A
- LGVN $8.67
- AVG Volume (30 Days)
- CTRM 50.0K
- LGVN 479.7K
- Earning Date
- CTRM 03-18-2025
- LGVN 02-28-2025
- Dividend Yield
- CTRM N/A
- LGVN N/A
- EPS Growth
- CTRM N/A
- LGVN N/A
- EPS
- CTRM 2.39
- LGVN N/A
- Revenue
- CTRM $76,443,340.00
- LGVN $2,392,000.00
- Revenue This Year
- CTRM N/A
- LGVN $26.05
- Revenue Next Year
- CTRM N/A
- LGVN $12.27
- P/E Ratio
- CTRM $1.02
- LGVN N/A
- Revenue Growth
- CTRM N/A
- LGVN 237.38
- 52 Week Low
- CTRM $2.33
- LGVN $0.77
- 52 Week High
- CTRM $5.49
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- CTRM 40.22
- LGVN 51.10
- Support Level
- CTRM $2.37
- LGVN $1.40
- Resistance Level
- CTRM $2.84
- LGVN $1.62
- Average True Range (ATR)
- CTRM 0.15
- LGVN 0.14
- MACD
- CTRM 0.00
- LGVN 0.01
- Stochastic Oscillator
- CTRM 15.69
- LGVN 72.73
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.